LR 103

Drug Profile

LR 103

Alternative Names: LR-103

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Antineoplastics; Antipsoriatics
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Hyperparathyroidism; Psoriasis

Most Recent Events

  • 28 Mar 2011 Discontinued - Phase-I for Cancer in USA (PO)
  • 28 Mar 2011 Discontinued - Preclinical for Hyperparathyroidism in USA (unspecified route)
  • 28 Mar 2011 Discontinued - Preclinical for Psoriasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top